Search

Your search keyword '"Woehrle Jochen"' showing total 161 results
Start Over Author "Woehrle Jochen"
161 results on '"Woehrle Jochen"'

4. Design and rationale of a prospective, randomized, non-inferiority trial to determine the safety and efficacy of the Biolimus A9™ drug coated balloon for the treatment of in-stent restenosis: First-in-man trial (REFORM)

Author

Traynor, Bryan P., Fitzgerald, Sean, Alfonso, Fernando, O'Kane, Peter, Sabaté, Manel, Tölg, Ralph, Trevelyan, Jasper, Hahn, Joo-Yong, Mylotte, Darren, Wöhrle, Jochen, Rai, Himanshu, Cortese, Bernardo, Morice, Marie-Claude, Schuette, Diane, Copt, Samuel, Oldroyd, Keith G., and Byrne, Robert A.

Published
2023
Full Text
View/download PDF

5. Incidence, Predictors, and Prognostic Impact of New Permanent Pacemaker Implantation After TAVR With Self-Expanding Valves

Author

Pagnesi, Matteo, Kim, Won-Keun, Baggio, Sara, Scotti, Andrea, Barbanti, Marco, De Marco, Federico, Adamo, Marianna, Eitan, Amnon, Estévez-Loureiro, Rodrigo, Conradi, Lenard, Toggweiler, Stefan, Mylotte, Darren, Veulemans, Verena, Søndergaard, Lars, Wolf, Alexander, Giannini, Francesco, Maffeo, Diego, Pilgrim, Thomas, Montorfano, Matteo, Zweiker, David, Ferlini, Marco, Kornowski, Ran, Hildick-Smith, David, Taramasso, Maurizio, Abizaid, Alexandre, Schofer, Joachim, Sinning, Jan-Malte, Van Mieghem, Nicolas M., Wöhrle, Jochen, Khogali, Saib, Van der Heyden, Jan A.S., Wood, David A., Ielasi, Alfonso, MacCarthy, Philip, Brugaletta, Salvatore, Hamm, Christian W., Costa, Giuliano, Testa, Luca, Massussi, Mauro, Alarcón, Robert, Schäfer, Ulrich, Brunner, Stephanie, Reimers, Bernhard, Lunardi, Mattia, Zeus, Tobias, Vanhaverbeke, Maarten, Naber, Christoph K., Di Ienno, Luca, Buono, Andrea, Windecker, Stephan, Schmidt, Albrecht, Lanzillo, Giuseppe, Vaknin-Assa, Hana, Arunothayaraj, Sandeep, Saccocci, Matteo, Siqueira, Dimytri, Brinkmann, Christina, Sedaghat, Alexander, Ziviello, Francesca, Seeger, Julia, Rottbauer, Wolfgang, Brouwer, Jorn, Buysschaert, Ian, Jelisejevas, Julius, Bharucha, Apurva, Regueiro, Ander, Metra, Marco, Colombo, Antonio, Latib, Azeem, and Mangieri, Antonio

Published
2023
Full Text
View/download PDF

6. Sealing of Coronary Perforations With a Second-Generation Covered Stent Graft - Results From the PAST-PERF Registry

Author

Birkemeyer, Ralf, Olivecrona, Göran K., Hellig, Farrel, Wöhrle, Jochen, Rottbauer, Wolfgang, Witkowski, Adam, Kuliczkowski, Wiktor, Bernhardt, Peter, Bettels, Nadine, Schrage, Benedikt, von zur Mühlen, Constantin, Cook, Stephane, Miljak, Tomislav, Eggbrecht, Holger, Eeckhout, Eric, Westermann, Dirk, Monsegu, Jaques, and Dumonteil, Nicolas

Published
2021
Full Text
View/download PDF

10. Current Generation Balloon-Expandable Transcatheter Valve Positioning Strategies During Aortic Valve-in-Valve Procedures and Clinical Outcomes

Author

Simonato, Matheus, Webb, John, Bleiziffer, Sabine, Abdel-Wahab, Mohamed, Wood, David, Seiffert, Moritz, Schäfer, Ulrich, Wöhrle, Jochen, Jochheim, David, Woitek, Felix, Latib, Azeem, Barbanti, Marco, Spargias, Konstantinos, Kodali, Susheel, Jones, Tara, Tchetche, Didier, Coutinho, Rafael, Napodano, Massimo, Garcia, Santiago, Veulemans, Verena, Siqueira, Dimytri, Windecker, Stephan, Cerillo, Alfredo, Kempfert, Jörg, Agrifoglio, Marco, Bonaros, Nikolaos, Schoels, Wolfgang, Baumbach, Hardy, Schofer, Joachim, Gaia, Diego Felipe, and Dvir, Danny

Published
2019
Full Text
View/download PDF

11. Transcatheter Aortic Valve Replacement With Next-Generation Self-Expanding Devices: A Multicenter, Retrospective, Propensity-Matched Comparison of Evolut PRO Versus Acurate neo Transcatheter Heart Valves

Author

Pagnesi, Matteo, Kim, Won-Keun, Conradi, Lenard, Barbanti, Marco, Stefanini, Giulio G., Zeus, Tobias, Pilgrim, Thomas, Schofer, Joachim, Zweiker, David, Testa, Luca, Taramasso, Maurizio, Hildick-Smith, David, Abizaid, Alexandre, Wolf, Alexander, Van Mieghem, Nicolas M., Sedaghat, Alexander, Wöhrle, Jochen, Khogali, Saib, Van der Heyden, Jan A.S., Webb, John G., Estévez-Loureiro, Rodrigo, Mylotte, Darren, MacCarthy, Philip, Brugaletta, Salvatore, Hamm, Christian W., Bhadra, Oliver D., Schäfer, Ulrich, Costa, Giuliano, Tamburino, Corrado, Cannata, Francesco, Reimers, Bernhard, Veulemans, Verena, Asami, Masahiko, Windecker, Stephan, Eitan, Amnon, Schmidt, Albrecht, Bianchi, Giovanni, Bedogni, Francesco, Saccocci, Matteo, Maisano, Francesco, Alsanjari, Osama, Siqueira, Dimytri, Jensen, Christoph J., Naber, Christoph K., Ziviello, Francesca, Sinning, Jan-Malte, Seeger, Julia, Rottbauer, Wolfgang, Brouwer, Jorn, Alenezi, Abdullah, Wood, David A., Tzalamouras, Vasileios, Regueiro, Ander, Colombo, Antonio, and Latib, Azeem

Published
2019
Full Text
View/download PDF

15. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial

Author

de Winter, Robbert J, Katagiri, Yuki, Asano, Taku, Milewski, Krzysztof P, Lurz, Philipp, Buszman, Pawel, Jessurun, Gillian A J, Koch, Karel T, Troquay, Roland P T, Hamer, Bas J B, Ophuis, Ton Oude, Wöhrle, Jochen, Wyderka, Rafał, Cayla, Guillaume, Hofma, Sjoerd H, Levesque, Sébastien, Żurakowski, Aleksander, Fischer, Dieter, Kośmider, Maciej, Goube, Pascal, Arkenbout, E Karin, Noutsias, Michel, Ferrari, Markus W, Onuma, Yoshinobu, Wijns, William, and Serruys, Patrick W

Published
2018
Full Text
View/download PDF

22. Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R)

Author

Nef, Holger, Wiebe, Jens, Achenbach, Stefan, Münzel, Thomas, Naber, Christoph, Richardt, Gert, Mehilli, Julinda, Wöhrle, Jochen, Neumann, Till, Biermann, Janine, Zahn, Ralf, Kastner, Johannes, Schmermund, Axel, Pfannebecker, Thomas, Schneider, Steffen, Limbourg, Tobias, and Hamm, Christian W.

Published
2016
Full Text
View/download PDF

23. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter)

Author

Rittger, Harald, Waliszewski, Matthias, Brachmann, Johannes, Hohenforst-Schmidt, Wolfgang, Ohlow, Marc, Brugger, Andreas, Thiele, Holger, Birkemeyer, Ralf, Kurowski, Volkhard, Schlundt, Christian, Zimmermann, Stefan, Lonke, Sandra, von Cranach, Moritz, Markovic, Sinisa, Daniel, Werner G., Achenbach, Stephan, and Wöhrle, Jochen

Published
2015
Full Text
View/download PDF

31. Two-year clinical outcomes after successful transcatheter aortic valve implantation with balloon-expandable versus self-expanding valves: A subanalysis of the GALILEO trial

Author

Okuno, Taishi, Dangas, George D., Hengstenberg, Christian, Sartori, Samantha, Herrmann, Howard C., de Winter, Robert, Gilard, Martine, Tchetche, Didier, Moellmann, Helge, Makkar, Raj R., Baldus, Stephan, De Backer, Ole, Bendz, Bjorn, Kini, Annapoorna, von Lewinski, Dirk, Mack, Michael, Moreno, Raul, Schaefer, Ulrich, Woehrle, Jochen, Seeger, Julia, Snyder, Clayton, Nicolas, Johny, Tijssen, Jan G. P., Welsh, Robert C., Vranckx, Pascal, Valgimigli, Marco, Mehran, Roxana, Kapadia, Samir, Sondergaard, Lars, Windecker, Stephan, Okuno, Taishi, Dangas, George D., Hengstenberg, Christian, Sartori, Samantha, Herrmann, Howard C., de Winter, Robert, Gilard, Martine, Tchetche, Didier, Moellmann, Helge, Makkar, Raj R., Baldus, Stephan, De Backer, Ole, Bendz, Bjorn, Kini, Annapoorna, von Lewinski, Dirk, Mack, Michael, Moreno, Raul, Schaefer, Ulrich, Woehrle, Jochen, Seeger, Julia, Snyder, Clayton, Nicolas, Johny, Tijssen, Jan G. P., Welsh, Robert C., Vranckx, Pascal, Valgimigli, Marco, Mehran, Roxana, Kapadia, Samir, Sondergaard, Lars, and Windecker, Stephan

Abstract

Background Midterm data comparing clinical outcomes after successful implantation of self-expanding and balloon-expandable transcatheter heart valves (THV) are limited. We aimed to compare 2-year outcomes after successful transcatheter aortic valve implantation (TAVI) with the Edwards balloon-expandable or the Medtronic self-expanding THV. Methods Two-year outcomes were analyzed according to the implanted THV in the GALILEO trial. Major adverse cardiac and cerebrovascular events (MACCE) was a composite of all-cause death or thromboembolic events including stroke, myocardial infarction, symptomatic valve thrombosis, systemic embolism, deep-vein thrombosis, or pulmonary embolism. Results Among 1644 patients recruited in 136 centers across 16 countries between 2015 and 2018, 499 received a self-expanding and 757 patients received a balloon-expandable THV. Patients treated with a self-expanding THV were more likely to be female, and had higher surgical risk, lower hemoglobin levels, and more frequent valve-in-valve procedures than those with a balloon-expandable THV. After multivariable adjustment, there were no significant differences in major clinical outcomes between self-expanding versus balloon-expandable THV: MACCE (17.0% vs. 13.4%, adjusted-hazard ratios [HR] 1.18, 95% confidence intervals [CI]: 0.82-1.69); all-cause death (11.4% vs. 9.3%, adjusted-HR 1.26; 95% CI: 0.78-2.05); cardiovascular death (8.5% vs. 4.0%, adjusted-HR 1.53; 95% CI: 0.82-2.86), any stroke (5.1% vs. 3.7%, adjusted-HR 0.86; 95% CI: 0.43-1.73); major or life-threatening bleeding (5.9% vs. 6.8%, adjusted-HR 0.93; 95% CI: 0.53-1.63). Clinical Trial Registration: . NCT02556203. Conclusions Two-year follow-up data from the GALILEO trial indicate that successful TAVI either with self-expanding or balloon-expandable THVs according to physician discretion did not show difference in rates of MACCE.

Published
2022

33. Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial

Author

Yu, Jennifer, Mehran, Roxana, Dangas, George D., Claessen, Bimmer E., Baber, Usman, Xu, Ke, Parise, Helen, Fahy, Martin, Lansky, Alexandra J., Witzenbichler, Bernhard, Grines, Cindy L., Guagliumi, Giulio, Kornowski, Ran, Wöhrle, Jochen, Dudek, Dariusz, Weisz, Giora, and Stone, Gregg W.

Published
2012
Full Text
View/download PDF

37. Impact of In-Hospital Major Bleeding on Late Clinical Outcomes After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial

Author

Suh, Jung-Won, Mehran, Roxana, Claessen, Bimmer E., Xu, Ke, Baber, Usman, Dangas, George, Parise, Helen, Lansky, Alexandra J., Witzenbichler, Bernhard, Grines, Cindy L., Guagliumi, Giulio, Kornowski, Ran, Wöhrle, Jochen, Dudek, Dariusz, Weisz, Giora, and Stone, Gregg W.

Published
2011
Full Text
View/download PDF

39. 90 Annular size and interaction with trans-catheter aortic valves for the treatment of severe bicuspid aortic valve stenosis: insights from the beat registry

Author

Moscarella, Elisabetta, primary, Mangieri, Antonio, additional, Giannini, Francesco, additional, Tchetchè, Didier, additional, Kim, Won-keun, additional, Sinning, Jan Malte, additional, Landes, Uri, additional, Kornowski, Ran, additional, Backer, Ole De, additional, Nickenig, George, additional, Biase, Chiara De, additional, Soendergaard, Lars, additional, Marco, Federico De, additional, Bedogni, Francesco, additional, Ancona, Marco, additional, Montorfano, Matteo, additional, Regazzoli, Damiano, additional, Stefanini, Giulio, additional, Toggweiler, Stefan, additional, Tamburino, Corrado, additional, Immè, Sebastiano, additional, Tarantini, Giuseppe, additional, Sievert, Horst, additional, Schaefer, Ulrich, additional, Kempfert, Jörg, additional, Woehrle, Jochen, additional, Latib, Azeem, additional, Calabrò, Paolo, additional, Medda, Massimo, additional, Tespili, Maurizio, additional, Colombo, Antonio, additional, and Ielasi, Alfonso, additional

Published
2021
Full Text
View/download PDF

43. Evaluation of Cerebral Thromboembolism After Transcatheter Aortic Valve Replacement (EARTH TAVR) A Serial Magnetic Resonance Imaging Evaluation as Substudy of the GALILEO Trial

Author

Froehlich, Georg Marcus, Endres, Matthias, Falk, Volkmar, Steinbeck, Lisa, Erbay, Aslihan, Stangl, Verena, Woehrle, Jochen, Rudolph, Tanja K., Geisler, Tobias, Dreger, Henryk, Leistner, David Manuel, Nolte, Christian H., Unbehaun, Axel, Linke, Axel, Fiebach, Jochen B., Majoie, Charles, Knapp, Guido, Georg Haeusler, Karl, Mehran, Roxana, Windecker, Stephan, Dangas, George D., Landmesser, Ulf, Froehlich, Georg Marcus, Endres, Matthias, Falk, Volkmar, Steinbeck, Lisa, Erbay, Aslihan, Stangl, Verena, Woehrle, Jochen, Rudolph, Tanja K., Geisler, Tobias, Dreger, Henryk, Leistner, David Manuel, Nolte, Christian H., Unbehaun, Axel, Linke, Axel, Fiebach, Jochen B., Majoie, Charles, Knapp, Guido, Georg Haeusler, Karl, Mehran, Roxana, Windecker, Stephan, Dangas, George D., and Landmesser, Ulf

Published
2021

44. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement

Author

Dangas, George D., Tijssen, Jan G. P., Woehrle, Jochen, Sondergaard, Lars, Gilard, Martine, Moellmann, Helge, Makkar, Raj R., Herrmann, Howard C., Giustino, Gennaro, Baldus, Stephan, De Backer, Ole, Guimaraes, Ana H. C., Gullestad, Lars, Kini, Annapoorna, von Lewinski, Dirk, Mack, Michael, Moreno, Raul, Schaefer, Ulrich, Seeger, Julia, Tchetche, Didier, Thomitzek, Karen, Valgimigli, Marco, Vranckx, Pascal, Welsh, Robert C., Wildgoose, Peter, Volkl, Albert A., Zazula, Ana, van Amsterdam, Ronald G. M., Mehran, Roxana, Windecker, Stephan, Dangas, George D., Tijssen, Jan G. P., Woehrle, Jochen, Sondergaard, Lars, Gilard, Martine, Moellmann, Helge, Makkar, Raj R., Herrmann, Howard C., Giustino, Gennaro, Baldus, Stephan, De Backer, Ole, Guimaraes, Ana H. C., Gullestad, Lars, Kini, Annapoorna, von Lewinski, Dirk, Mack, Michael, Moreno, Raul, Schaefer, Ulrich, Seeger, Julia, Tchetche, Didier, Thomitzek, Karen, Valgimigli, Marco, Vranckx, Pascal, Welsh, Robert C., Wildgoose, Peter, Volkl, Albert A., Zazula, Ana, van Amsterdam, Ronald G. M., Mehran, Roxana, and Windecker, Stephan

Abstract

Background Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear. Methods We randomly assigned 1644 patients without an established indication for oral anticoagulation after successful TAVR to receive rivaroxaban at a dose of 10 mg daily (with aspirin at a dose of 75 to 100 mg daily for the first 3 months) (rivaroxaban group) or aspirin at a dose of 75 to 100 mg daily (with clopidogrel at a dose of 75 mg daily for the first 3 months) (antiplatelet group). The primary efficacy outcome was the composite of death or thromboembolic events. The primary safety outcome was major, disabling, or life-threatening bleeding. The trial was terminated prematurely by the data and safety monitoring board because of safety concerns. Results After a median of 17 months, death or a first thromboembolic event (intention-to-treat analysis) had occurred in 105 patients in the rivaroxaban group and in 78 patients in the antiplatelet group (incidence rates, 9.8 and 7.2 per 100 person-years, respectively; hazard ratio with rivaroxaban, 1.35; 95% confidence interval [CI], 1.01 to 1.81; P=0.04). Major, disabling, or life-threatening bleeding (intention-to-treat analysis) had occurred in 46 and 31 patients, respectively (4.3 and 2.8 per 100 person-years; hazard ratio, 1.50; 95% CI, 0.95 to 2.37; P=0.08). A total of 64 deaths occurred in the rivaroxaban group and 38 in the antiplatelet group (5.8 and 3.4 per 100 person-years, respectively; hazard ratio, 1.69; 95% CI, 1.13 to 2.53). Conclusions In patients without an established indication for oral anticoagulation after successful TAVR, a treatment strategy including rivaroxaban at a dose of 10 mg daily was associated with a higher risk of death or thromboembolic complications and a higher risk of bleeding than an antiplatelet-based strategy. (Funded by Bayer and Janssen Pharmaceuticals; GALILEO ClinicalTrials.gov number, NCT02556203.)

Published
2020

45. Risk factors for permanent pacemaker implantation in patients receiving a balloon-expandable transcatheter aortic valve prosthesis

Author

Droppa, Michal, Rudolph, Tanja K., Baan, Jan, Nielsen, Niels-Erik, Baumgartner, Helmut, Vendrik, Jeroen, Froehlich, Maren, Borst, Oliver, Woehrle, Jochen, Gawaz, Meinrad, Potratz, Paul, Hack, Luis P., Mauri, Victor, Baranowski, Jacek, Bramlage, Peter, Kurucova, Jana, Thoenes, Martin, Rottbauer, Wolfgang, Geisler, Tobias, Droppa, Michal, Rudolph, Tanja K., Baan, Jan, Nielsen, Niels-Erik, Baumgartner, Helmut, Vendrik, Jeroen, Froehlich, Maren, Borst, Oliver, Woehrle, Jochen, Gawaz, Meinrad, Potratz, Paul, Hack, Luis P., Mauri, Victor, Baranowski, Jacek, Bramlage, Peter, Kurucova, Jana, Thoenes, Martin, Rottbauer, Wolfgang, and Geisler, Tobias

Abstract

Permanent pacemaker implantation (PPI) is a widely recognized complication associated with TAVI (incidence up to 20%). Smaller registries have identified several variables associated with PPI. The objective was to validate patient- and transcatheter aortic valve implantation (TAVI)-related procedural variables associated with PPI. We performed a retrospective analysis of patients from six European centers undergoing TAVI with the Edwards SAPIEN 3 prosthesis. Baseline variables and pre-procedural ECG characteristics and CT-scans were taken into account. Data for 1745 patients were collected; 191 (10.9%) required PPI after TAVI. The baseline variables pulmonary hypertension (OR 1.64; 95% CI 1.01-2.59), QRS duration > 117 ms (OR 2.58; 95% CI 1.73-3.84), right bundle branch block (RBBB; OR 5.14; 95% CI 3.39-7.72), left anterior hemi block (OR 1.92; 95% CI 1.19-3.02) and first-degree atrioventricular block (AVB, OR 1.63; 95%CI 1.05-2.46) were significantly associated with PPI. RBBB (OR 8.11; 95% CI 3.19-21.86) and first-degree AVB (OR 2.39; 95% CI 1.18-4.66) remained significantly associated in a multivariate analysis. Procedure-related variables included access site (TF; OR 1.97; 95% CI 1.07-4.05), implanted valve size (29 mm; OR 1.88; 95% CI 1.35-2.59), mean TAVI valve implantation depth below the annulus > 30% (OR 3.75; 95% CI 2.01-6.98). Patients receiving PPI had longer ICU stays and later discharges. Acute kidney injury stage 2/3 was more common in patients with PPI until discharge (15.2 vs. 3.1%;p = 0.007), but was not statistically significant thereafter. Further differences in outcomes at 30 days did not reach significance. The data will aid pre- and post-procedural patient management and prevent adverse long-term outcomes. Clinical Trial: NCT03497611.

Published
2020

46. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

Author

Neumann, Franz Josef, Sechtem, Udo, Banning, Adrian Paul, Bonaros, Nikolaos, Bueno, Héctor, Bugiardini, Raffaele, Chieffo, Alaide, Crea, Filippo, Czerny, Martin, Delgado, Victoria, Dendale, Paul, Knuuti, Juhani, Wijns, William, Flachskampf, Frank Arnold, Gohlke, Helmut, Grove, Erik Lerkevang, James, Stefan, Katritsis, Demosthenes, Landmesser, Ulf, Lettino, Maddalena, Matter, Christian M., Nathoe, Hendrik, Niessner, Alexander, Patrono, Carlo, Petronio, Anna Sonia, Pettersen, Steffen E., Piccolo, Raffaele, Piepoli, Massimo Francesco, Popescu, Bogdan A., Räber, Lorenz, Richter, Dimitrios J., Roffi, Marco, Roithinger, Franz X., Shlyakhto, Evgeny, Sibbing, Dirk, Silber, Sigmund, Simpson, Iain A., Sousa-Uva, Miguel, Vardas, Panos, Witkowski, Adam, Zamorano, Jose Luis, Achenbach, Stephan, Agewall, Stefan, Barbato, Emanuele, Bax, Jeroen J., Capodanno, Davide, Cuisset, Thomas, Deaton, Christi, Dickstein, Kenneth, Edvardsen, Thor, Escaned, Javier, Funck-Brentano, Christian, Gersh, Bernard J., Gilard, Martine, Hasdai, David, Hatala, Robert, Mahfoud, Felix, Masip, Josep, Muneretto, Claudio, Prescott, Eva, Saraste, Antti, Storey, Robert F., Svitil, Pavel, Valgimigli, Marco, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Fitzsimons, Donna, Gale, Christopher P., Grobbee, Diederick E., Halvorsen, Sigrun, Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Leclercq, Christophe, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen, Touyz, Rhian M., Benkhedda, Salim, Metzler, Bernhard, Sujayeva, Volha, Cosyns, Bernard, Kusljugic, Zumreta, Velchev, Vasil, Panayi, Georgios, Kala, Petr, Haahr-Pedersen, Sune Ammentorp, Kabil, Hamza, Ainla, Tiia, Kaukonen, Tomi, Cayla, Guillaume, Pagava, Zurab, Woehrle, Jochen, Kanakakis, John, Toth, Kalman, Gudnason, Thorarinn, Peace, Aaron, Aronson, Doron, Riccio, Carmine, Elezi, Shpend, Mirrakhimov, Erkin, Hansone, Silvija, Sarkis, Antoine, Babarskiene, Ruta, Beissel, Jean, Cassar Maempel, Andrew J., Revenco, Valeriu, de Grooth, G. J., Pejkov, Hristo, Juliebø, Vibeke, Lipiec, Piotr, Santos, Jose, Chioncel, Ovidiu, Duplyakov, Dmitry, Bertelli, Luca, Dikic, Ana Djordjevic, Studencan, Martin, Bunc, Matjaz, Alfonso, Fernando, Back, Magnus, Zellweger, Michael, Addad, Faouzi, Yildirir, Aylin, Sirenko, Yuriy, Clapp, Brian, Neumann, Franz Josef, Sechtem, Udo, Banning, Adrian Paul, Bonaros, Nikolaos, Bueno, Héctor, Bugiardini, Raffaele, Chieffo, Alaide, Crea, Filippo, Czerny, Martin, Delgado, Victoria, Dendale, Paul, Knuuti, Juhani, Wijns, William, Flachskampf, Frank Arnold, Gohlke, Helmut, Grove, Erik Lerkevang, James, Stefan, Katritsis, Demosthenes, Landmesser, Ulf, Lettino, Maddalena, Matter, Christian M., Nathoe, Hendrik, Niessner, Alexander, Patrono, Carlo, Petronio, Anna Sonia, Pettersen, Steffen E., Piccolo, Raffaele, Piepoli, Massimo Francesco, Popescu, Bogdan A., Räber, Lorenz, Richter, Dimitrios J., Roffi, Marco, Roithinger, Franz X., Shlyakhto, Evgeny, Sibbing, Dirk, Silber, Sigmund, Simpson, Iain A., Sousa-Uva, Miguel, Vardas, Panos, Witkowski, Adam, Zamorano, Jose Luis, Achenbach, Stephan, Agewall, Stefan, Barbato, Emanuele, Bax, Jeroen J., Capodanno, Davide, Cuisset, Thomas, Deaton, Christi, Dickstein, Kenneth, Edvardsen, Thor, Escaned, Javier, Funck-Brentano, Christian, Gersh, Bernard J., Gilard, Martine, Hasdai, David, Hatala, Robert, Mahfoud, Felix, Masip, Josep, Muneretto, Claudio, Prescott, Eva, Saraste, Antti, Storey, Robert F., Svitil, Pavel, Valgimigli, Marco, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Fitzsimons, Donna, Gale, Christopher P., Grobbee, Diederick E., Halvorsen, Sigrun, Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Leclercq, Christophe, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen, Touyz, Rhian M., Benkhedda, Salim, Metzler, Bernhard, Sujayeva, Volha, Cosyns, Bernard, Kusljugic, Zumreta, Velchev, Vasil, Panayi, Georgios, Kala, Petr, Haahr-Pedersen, Sune Ammentorp, Kabil, Hamza, Ainla, Tiia, Kaukonen, Tomi, Cayla, Guillaume, Pagava, Zurab, Woehrle, Jochen, Kanakakis, John, Toth, Kalman, Gudnason, Thorarinn, Peace, Aaron, Aronson, Doron, Riccio, Carmine, Elezi, Shpend, Mirrakhimov, Erkin, Hansone, Silvija, Sarkis, Antoine, Babarskiene, Ruta, Beissel, Jean, Cassar Maempel, Andrew J., Revenco, Valeriu, de Grooth, G. J., Pejkov, Hristo, Juliebø, Vibeke, Lipiec, Piotr, Santos, Jose, Chioncel, Ovidiu, Duplyakov, Dmitry, Bertelli, Luca, Dikic, Ana Djordjevic, Studencan, Martin, Bunc, Matjaz, Alfonso, Fernando, Back, Magnus, Zellweger, Michael, Addad, Faouzi, Yildirir, Aylin, Sirenko, Yuriy, and Clapp, Brian

Abstract

Coronary artery disease (CAD) is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries, whether obstructive or non-obstructive. This process can be modified by lifestyle adjustments, pharmacological therapies, and invasive interventions designed to achieve disease stabilization or regression. The disease can have long, stable periods but can also become unstable at any time, typically due to an acute atherothrombotic event caused by plaque rupture or erosion. However, the disease is chronic, most often progressive, and hence serious, even in clinically apparently silent periods. The dynamic nature of the CAD process results in various clinical presentations, which can be conveniently categorized as either acute coronary syndromes (ACS) or chronic coronary syndromes (CCS). The Guidelines presented here refer to the management of patients with CCS. The natural history of CCS is illustrated in Figure 1.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results